Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial.
dose escalation
glioblastoma
malignant glioma
mebendazole
phase 1 clinical trial
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
29
1
2021
Statut:
epublish
Résumé
Mebendazole is an anthelmintic drug introduced for human use in 1971 that extends survival in preclinical models of glioblastoma and other brain cancers. A single-center dose-escalation and safety study of mebendazole in 24 patients with newly diagnosed high-grade gliomas in combination with temozolomide was conducted. Patients received mebendazole in combination with adjuvant temozolomide after completing concurrent radiation plus temozolomide. Dose-escalation levels were 25, 50, 100, and 200 mg/kg/day of oral mebendazole. A total of 15 patients were enrolled at the highest dose studied of 200 mg/kg/day. Trough plasma levels of mebendazole were measured at 4, 8, and 16 weeks. Twenty-four patients (18 glioblastoma and 6 anaplastic glioma) were enrolled with a median age of 49.8 years. Four patients (at 200 mg/kg) developed elevated grade 3 alanine aminotransferase (ALT) and/or aspartate transaminase (AST) after 1 month, which reversed with lower dosing or discontinuation. Plasma levels of mebendazole were variable but generally increased with dose. Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years. Median progression-free survival (PFS) from the date of diagnosis for 17 patients taking more than 1 month of mebendazole was 13.1 months (95% confidence interval [CI]: 8.8-14.6 months) but for 7 patients who received less than 1 month of mebendazole PFS was 9.2 months (95% CI: 5.8-13.0 months). Mebendazole at doses up to 200 mg/kg demonstrated long-term safety and acceptable toxicity. Further studies are needed to determine mebendazole's efficacy in patients with malignant glioma.
Sections du résumé
BACKGROUND
BACKGROUND
Mebendazole is an anthelmintic drug introduced for human use in 1971 that extends survival in preclinical models of glioblastoma and other brain cancers.
METHODS
METHODS
A single-center dose-escalation and safety study of mebendazole in 24 patients with newly diagnosed high-grade gliomas in combination with temozolomide was conducted. Patients received mebendazole in combination with adjuvant temozolomide after completing concurrent radiation plus temozolomide. Dose-escalation levels were 25, 50, 100, and 200 mg/kg/day of oral mebendazole. A total of 15 patients were enrolled at the highest dose studied of 200 mg/kg/day. Trough plasma levels of mebendazole were measured at 4, 8, and 16 weeks.
RESULTS
RESULTS
Twenty-four patients (18 glioblastoma and 6 anaplastic glioma) were enrolled with a median age of 49.8 years. Four patients (at 200 mg/kg) developed elevated grade 3 alanine aminotransferase (ALT) and/or aspartate transaminase (AST) after 1 month, which reversed with lower dosing or discontinuation. Plasma levels of mebendazole were variable but generally increased with dose. Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years. Median progression-free survival (PFS) from the date of diagnosis for 17 patients taking more than 1 month of mebendazole was 13.1 months (95% confidence interval [CI]: 8.8-14.6 months) but for 7 patients who received less than 1 month of mebendazole PFS was 9.2 months (95% CI: 5.8-13.0 months).
CONCLUSION
CONCLUSIONS
Mebendazole at doses up to 200 mg/kg demonstrated long-term safety and acceptable toxicity. Further studies are needed to determine mebendazole's efficacy in patients with malignant glioma.
Identifiants
pubmed: 33506200
doi: 10.1093/noajnl/vdaa154
pii: vdaa154
pmc: PMC7817892
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa154Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
J Neurooncol. 2018 Dec;140(3):529-538
pubmed: 30414098
Mol Cancer Ther. 2015 Jan;14(1):3-13
pubmed: 25376612
Toxicol In Vitro. 2015 Dec;29(8):2038-44
pubmed: 26315676
Sci Rep. 2016 Sep 21;6:33534
pubmed: 27650168
Oncotarget. 2017 Feb 21;8(8):12576-12595
pubmed: 28157711
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):195-207
pubmed: 30196056
Oncotarget. 2016 Oct 18;7(42):68571-68584
pubmed: 27612418
Arch Toxicol. 2011 Mar;85(3):199-207
pubmed: 20848085
Arch Dis Child. 1991 Apr;66(4):532-3
pubmed: 2031617
J Vet Pharmacol Ther. 2004 Apr;27(2):85-90
pubmed: 15096105
Ann Intern Med. 1979 Oct;91(4):582-6
pubmed: 484964
BMC Res Notes. 2019 Apr 22;12(1):234
pubmed: 31010428
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Am J Trop Med Hyg. 1984 Jan;33(1):132-7
pubmed: 6696172
JAMA. 1983 Jun 3;249(21):2929-31
pubmed: 6842806
Clin Cancer Res. 2015 Aug 1;21(15):3462-3470
pubmed: 25862759
Mol Cancer Ther. 2002 Nov;1(13):1201-9
pubmed: 12479701
Cancer Chemother Pharmacol. 2008 Apr;61(5):809-17
pubmed: 17581752
Mol Cancer Res. 2008 Aug;6(8):1308-15
pubmed: 18667591
Am J Public Health. 2003 Mar;93(3):489-92
pubmed: 12604501
Endocr Pract. 2011 May-Jun;17(3):e59-62
pubmed: 21454232
Vet Comp Oncol. 2017 Dec;15(4):1445-1454
pubmed: 28078780
Acta Oncol. 2014 Mar;53(3):427-8
pubmed: 24160353
J Cancer Res Clin Oncol. 2013 Dec;139(12):2133-40
pubmed: 24135855
Clin Cancer Res. 2002 Sep;8(9):2963-9
pubmed: 12231542
Anticancer Drugs. 2013 Feb;24(2):181-8
pubmed: 23059386
J Med Chem. 2018 May 10;61(9):3918-3929
pubmed: 29648826
Southeast Asian J Trop Med Public Health. 2014 Nov;45(6):1264-70
pubmed: 26466412
Neuro Oncol. 2015 Apr;17(4):545-54
pubmed: 25253417
Mol Med. 2017 Apr;23:50-56
pubmed: 28386621
Oncotarget. 2017 Feb 21;8(8):12968-12982
pubmed: 28099902
Am J Trop Med Hyg. 1980 Nov;29(6):1356-8
pubmed: 7446825
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neuro Oncol. 2011 Sep;13(9):974-82
pubmed: 21764822